Prognostic value of Iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy

Japanese Circulation Journal

Volumn 65, Issue 3, 2001, Pages 155-160

  Imamura, Y ^a   Fukuyama, T ^a   Mochizuki, T ^a   Miyagawa, M ^a   Watanabe, K ^a  

^a MATSUYAMA RED CROSS HOSPITAL   (Japan)

Author keywords

Cardiac natriuretic; Cardiomyopathy; MIBG imaging; Peptides; Prognosis

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NATRIURETIC FACTOR; RADIOISOTOPE;

ARTICLE; CARDIOMYOPATHY; DIAGNOSTIC IMAGING; FEMALE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RADIOISOTOPE DIAGNOSIS; REGRESSION ANALYSIS;

3-IODOBENZYLGUANIDINE; AGED; ATRIAL NATRIURETIC FACTOR; CARDIOMYOPATHIES; DEATH; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0035107334     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.65.155     Document Type: Article

References (38)

1. Prognostic Importance of atrial natriuretic peptide in patients with chronic heart failure
2. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure
3. Effect of long-term enalapril therapy on neurohormons in patients with left ventricular dysfunction
4. Plasma norepinephrine as a guide to prognosis in patients with heart failure
5. Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure
6. Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzlguanidine
7. Iodine-123 Metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants
8. Cardiac studies with metaiodobenzylguanidine: A critique of methods and interpretation of results
9. I-123 metaiodobenzylguanidine imagings reflect the intense myocardial adrenergic nervous activity of congestive heart failure independent from the underlying cause
10. Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload
11. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with HF
12. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy
13. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure
14. 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after β-blocker or angiotensin-converting enzyme inhibotor therapy
15. Metaiodobenzylguanidine imaging in diabetes mellitus: Assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia
16. Enhanced cardiac clearance of iodine-123-MIBG in chronic renal failure
17. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man
18. 123I] metaiodobenzylguanidine scintigraphy
19. Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes
20. Scintigraphic assessment of MIBG uptake globally denervated human and canine hearts: Implication for clinical studies
21. 123I-MIBG myocardial scintigraphy and power spectral analysis of heart rate variabiity
22. 123I-MIBG
23. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy
24. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure
25. 123I-MIBG uptake and increased clearance in various cardiac diseases
26. Modulation of left ventricular iodine125-MIBG accumulation in cardiomyopathic syrian hamsters using the renin-angiotensin system
27. Sympathetic tone assessed by washout of iodine 125-labeled metaiodobenzylguanidine from the murine left ventricle-influence of immobilization stress and inhibition of the renin-angiotensin system
28. Assessment of adrenergic nerve function altered with progression of heart failure
29. Comparison between iodine 123 metaiodobenzylguanidine scintigraphy and heart rate variability for the assessment of cardiac sympathetic activity in mild to moderate heart failure
30. Metaiodobenzylguanidine and heart rate variability in heart failure
31. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: Relationship with peak oxygen uptake and prognosis
32. Assessment of most appropriate background subtraction method for quantification of 123I-metaiodobenzylguanidine (MIBG) myocardial uptake by comparing with plasma anp and bnp
33. Regional cardiac sympathetic nerve dysfunction and the diagnostic efficacy of metaiodobenzylguanidine tomography in stable coronary artery disease
34. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
35. Hemodynamic, renal, and hormonal response to brain natriuretic peptide infusion in patients with congestive heart failure
36. Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure
37. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
38. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of β-blocker therapy for congestive heart failure